Shared Decision-Making in Major Depressive Disorder
Shared Decision-Making in Major Depressive Disorder Webinar
You will be directed to
PlatformQ Health Education's
PsychiatryCareLive website to register and participate in the webcast.
Major depressive disorder (MDD) has substantial negative effects on patients’ functional abilities and quality of life. However, shared decision-making has been shown to improve patients’ engagement with MDD care, fostering a team-based approach that includes mutually agreed upon treatment goals and improves treatment outcomes.
This webcast will focus on how to strengthen this therapeutic alliance to promote a cooperative, team-based approach that leads to success.
Approved for up to 1 AAFP Prescribed credit.
This activity is jointly provided by American Academy of Family Physicians and PlatformQ Health Education, LLC.
After completing this CME activity, you should be able to:
- Recognize the full symptomatic and functional burden that MDD places on patients, improving their abilities to communicate with patients from a position of greater empathy and strengthening the therapeutic alliance
- Use an SDM approach to MDD treatment selection, taking into account the clinical characteristics of current pharmacologic therapies for MDD, including efficacy, tolerability, and practical considerations of importance to patients
- Apply the principles of SDM to assessing, monitoring, and maintaining patient adherence with pharmacologic therapy for MDD, by enhancing patient understanding of the treatment process and fostering a team-based approach to shared treatment goals
Estimated time required to complete the activity: 1 hour
Recorded from the live webinar on December 13, 2017.
Margaret L. Smith, MD, MPH, MHSA, Assistant Professor, Department of Family Medicine, University of Kansas
Tonya L. Fancher, MD, MPH, Professor, Department of Internal Medicine, Division of General Medicine, Associate Dean, University of California at Davis School of Medicine.
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
This Enduring Material activity, Shared Decision-Making in Major Depressive Disorder, has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. Term of approval begins 12/13/17. Term of approval is for 1 year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of the American Academy of Family Physicians (AAFP) and PlatformQ Health Education, LLC (PQHE). The AAFP is accredited by the ACCME to provide continuing medical education for physicians.
The American Academy of Family Physicians designates this Enduring Material activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME activities approved for AAFP credit are recognized by the AOA as equivalent to AOA Category 2 credit.
It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and, if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.
The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
Disclosure of Unlabeled/Investigational Uses of Products
Faculty shall disclose when an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during an educational activity. Faculty shall disclose that the product is not labeled for the use under discussion or that the product is still investigational.
It is not the purpose of this policy to prohibit or limit the exchange of views in scientific and educational discussions, including discussion of unapproved uses, but to ensure that faculty discloses to participants that such discussion will take place.